Articles

Podcasts

Videos

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West. 

Rajeev Raghavan, MD, Discusses Updated ADA Guidelines for Diabetic Kidney Disease

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Rajeev Raghavan, MD: SGLT2 Inhibitors and GLP-1 Receptor Agonists

Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.

Rajeev Raghavan, MD, Talks About the Underutilized Therapeutics in Nephrology

Dr. Miriam Vos details the TARGET-NASH study, which indicated a higher prevalence of NAFLD in pediatric patients than previously thought.

NAFLD Prevalence Increasing in Pediatric Patients

The VersiPD Cycler System is expected to be available in the US in 2022. 

FDA Clears New Quiet, Portable Dialysis System

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Triple Combination Pill Shows Substantial Increase in Time at Target Blood Pressure

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

A Preview of the Ziltevekimab ZEUS Clinical Trial

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

CANTOS Data Show Importance of Inflammation Risk in CKD Patients with Atherosclerosis

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D. 

Javed Butler, MD: Consistent Benefits of Finerenone On CV, Kidney Outcomes 

Study author Deepak L. Bhatt, MD, MPH, discusses the unique SGLT-1 and SGLT-2 inhibition derived from sotagliflozin, and how impactful its benefit may be.

Sotagliflozin Reduces MACE Risk in Diabetic, Kidney Disease Patients in SCORED Trial

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.